TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31939036
Drug: Intradermal botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal botulinum toxin A (50 units)
Study: 19138360
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once a day
Study: 19138360
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on alternative days
Study: 19138360
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alfuzosin and tadalafil
Study: 11190581
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/day (n = 12)
Study: 9332997
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at a rate of 1 to 5 microg/kg per minute
Study: 2877643
Drug: Beta-blockade with
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade with betaxolol (oral, cardioselective) during clinical beta-blockade (heart rate 50 to 60 beats per minute, <20% increase in heart rate over baseline during stage I treadmill exercise, Bruce protocol)
Study: 29763434
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen 3 times a day for 3 days
Study: 29763434
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pivmecillinam 3 times a day for 3 days
Study: 27150261
Drug: ABT-981 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-981 (0.3, 1, 3, or 10 mg/kg intravenously; 0.3, 1, 3 mg/kg subcutaneously)
Study: 27150261
Drug: ABT-981 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-981 (3 mg/kg subcutaneously every 4 weeks)
Study: 27150261
Drug: ABT-981 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-981 (subcutaneous doses every 2 weeks)
Study: 19661958
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet + 500 ml water prior to each daily meal (water group)
Study: 19661958
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml water preload (WP)
Study: 18598003
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of bimosiamose
Study: 15860254
Drug: Spironolactone (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (low doses) added to standard of care
Study: 15860254
Drug: Eplerenone (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (selective MR antagonist)
Study: 8694020
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g lactose (lactose-free milk)
Study: 8694020
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g lactose
Study: 8694020
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g lactose
Study: 8694020
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g lactose
Study: 29499976
Drug: 350 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 μg/week sublingual vitamin B12 (Ld)
Study: 29499976
Drug: 2000 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 μg/week sublingual vitamin B12 (Hd)
Study: 28093634
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates therapy
Study: 28093634
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of bone turnover markers (BTMs) PINP and CTX at baseline and 3 months after starting therapy
Study: 26094080
Drug: Panitumumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (9 mg/kg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Study: 27311415
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg calcium supplementation
Study: 8091142
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bid (subgroup of N = 123)
Study: 23216762
Drug: Artificial gravity
Normalized name: SPECIFIC GRAVITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial gravity (AG) exercise countermeasure (CM) group, exposed to AG for 30 min, twice daily, with ergometric exercise at 40 W intensity.
Study: 19238653
Drug: RWJ-800088 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-800088 (doses > or = 0.75 microg/kg)
Study: 19238653
Drug: RWJ-800088 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-800088 (doses 2.5 and 3.0 microg/kg)
Study: 19238653
Drug: RWJ-800088 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-800088 (two highest doses)
Study: 11003347
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks)
Study: 11003347
Drug: i.v. ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ganciclovir (5 mg/kg q 12 hr for 7 days)
Study: 11003347
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral prophylaxis (for patients without CMV antigenemia)
Study: 1824
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg d-amphetamine
Study: 23988908
Drug: Dentifrice containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing insoluble calcium compound and 1,450 ppm fluoride
Study: 20573923
Drug: Fractional doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional doses of inactivated poliovirus vaccine (0.1 ml, intradermally)
Study: 20573923
Drug: Full doses
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full doses of inactivated poliovirus vaccine (intramuscularly)
Study: 20573923
Drug: Fractional doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional doses of inactivated poliovirus vaccine
Study: 20573923
Drug: Full doses
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full doses of inactivated poliovirus vaccine
Study: 18769864
Drug: Oral levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral levetiracetam (LEV) 500 mg twice daily
Study: 16835214
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 150 mg daily
Study: 14693303
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg, titrated to 160 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Study: 14693303
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg, titrated to 10 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Study: 10753002
Drug: Metrifonate 30-60
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 30-60 mg
Study: 6357936
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, acute administration)
Study: 6357936
Drug: Propranolol (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (chronic administration, dosage reducing heart rate by 25%)
Study: 6357936
Drug: Propranolol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (acute and chronic administration)
Study: 26626336
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (n=10) performing barbell back squats and deadlifts twice per week for four weeks
Study: 19903658
Drug: AA plus
Normalized name: Homactin AA plus 20PE Suspension (Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA plus G (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%)
Study: 17699390
Drug: G only
Normalized name: Selexipag only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: G only (control dialysate)
Study: 18572233
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) intervention with bupropion and nicotine patch, including a pedometer, counseling to increase steps by 10% biweekly towards a 10,000 steps/day goal, and personalized reports for 40 weeks.
Study: 18572233
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) intervention with bupropion and nicotine patch.
Study: 9532686
Drug: Hep-A-in-Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hep-A-in-Vac vaccine
Study: 7976448
Drug: Medication-free clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free clinical treatment
Study: 31022252
Drug: Preventive treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatments for RA (e.g., non-biologic drugs like hydroxychloroquine, atorvastatin, biologics)
Study: 31022252
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment vs. infusion
Study: 30573748
Drug: Licensed trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed trivalent influenza vaccine
Study: 30573748
Drug: Novel virus-like
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel virus-like particle based vaccine
Study: 26986471
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (ISTp) with dihydroartemisinin-piperaquine (DP)
Study: 26986471
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP)
Study: 26986471
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Study: 25210017
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral lenalidomide (20 mg/day)
Study: 19050386
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg intravenous)
Study: 11600352
Drug: Reference capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference capsule formulation of amoxicillin
Study: 11600352
Drug: Test capsule
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test capsule formulation of amoxicillin
Study: 11600352
Drug: Reference and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference and test suspensions of amoxicillin
Study: 11600352
Drug: Various amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various amoxicillin formulations (250 to 1,000 mg)
Study: 11600352
Drug: Two-point LSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-point LSS models for T>MICs of 0.25 or 2.0 microg/ml
Study: 3120487
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg selegiline (1‐deprenyl)
Study: 3120487
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Madopar + 10 mg selegiline (1‐deprenyl)
Study: 3120487
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Madopar + placebo
Study: 23575810
Drug: Vigabatrin (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (3.0 g/d)
Study: 19912207
Drug: Tolterodine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine combined with behavioral therapies including individualized fluid management instructions
Study: 16316699
Drug: Coronary risk
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary risk factors and inflammation assessment in CAD patients with ICD implants
Study: 8993956
Drug: Homoeopathic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic therapy (n = 30)
Study: 8993956
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (n = 30)
Study: 7703597
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition (IVN) for 10 days
Study: 18424600
Drug: Full-dose muffins
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose muffins (control)
Study: 17587720
Drug: Amiodarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (400 mg/day) 2 months before PTMV
Study: 17587720
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg/day) after cardioversion
Study: 9579811
Drug: PGI/MN II
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGI/MN II monoclonal antibodies
Study: 9579811
Drug: D8/17 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: D8/17 monoclonal antibodies
Study: 7607786
Drug: 5-ASA at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA at 2.4 g/day in a delayed-release formulation (Eudragit-S-coated Mesaline)
Study: 7607786
Drug: Non-specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific therapy (Control group)
Study: 10919899
Drug: Valaciclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (500 mg, three times daily)
Study: 10919899
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg, five times daily)
Study: 1451073
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy (AHRT) at 48.0 Gy
Study: 1451073
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy (AHRT) at 54.4 Gy
Study: 1451073
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy (RT) and bis-chloroethyl nitrosourea (BCNU) for patients 60 years or older
Study: 30591391
Drug: Photobiomodulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation with low-level laser therapy (LLLT)
Study: 29464587
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day vonoprazan
Study: 29464587
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day lansoprazole
Study: 27306921
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (specific dosage and duration not available)
Study: 25281675
Drug: Traditional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional preparation methods
Study: 20920044
Drug: intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive insulin therapy (IIT)
Study: 18040529
Drug: Tiotropium inhalation
Normalized name: Tiotropium Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium inhalation
Study: 2287555
Drug: Tourniquet inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet inflation at 5 minutes after cefazolin administration
Study: 2287555
Drug: Tourniquet inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet inflation at 2 minutes after cefazolin administration
Study: 2287555
Drug: Tourniquet inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet inflation at 1 minute after cefazolin administration
Study: 6973989
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluproquazone
Study: 28118533
Drug: Subcutaneous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous belimumab 200 mg weekly
Study: 23406311
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate drinks and postoperative polymeric supplement drinks
Study: 19703126
Drug: DTPa2 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa2 and DTPa3 vaccines
Study: 19703126
Drug: IgG anti-Fim2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG anti-Fim2/3 levels > or =5 EU/ml
Study: 11151742
Drug: Caffeine 2.1
Normalized name: caffeine 2.17 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2.1 mg kg‐1 body weight (low dose)
Study: 11151742
Drug: Caffeine 4.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4.3 mg kg‐1 body weight (medium dose)
Study: 11151742
Drug: Caffeine 8.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 8.6 mg kg‐1 body weight (high dose)
Study: 2871783
Drug: Bevantolol 200
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 200 to 400 mg/day
Study: 29210953
Drug: Citrulline Malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline Malate (CM) 8 g
Study: 22998687
Drug: Esomeprazole (ESO)
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole (ESO) treatment for 5 years
Study: 9457819
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX RT) with a thoracic spinal cord dose of 50.4 Gy given via 1.2 Gy b.i.d. fractionation
Study: 2612558
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 360 mg at 22.00 h
Study: 2612558
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 360 mg at 08.00 h
Study: 2612558
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 360 mg at night (24.00 h-06.00 h)
Study: 28981543
Drug: Daily 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 4% chlorhexidine care
Study: 25939018
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy (CPT-C)
Study: 16261517
Drug: Meta050 (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta050 (440 mg three times a day for 4 weeks, then 880 mg twice a day for 4 weeks)
Study: 12072677
Drug: Coupled plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coupled plasma filtration adsorption plus hemodialysis (treatment A)
Study: 12072677
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous hemodiafiltration (treatment B)
Study: 2224694
Drug: High-dose zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zidovudine therapy
Study: 2224694
Drug: Low-dose zidovudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose zidovudine therapy
Study: 27393080
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/day orally) with EE/LNG
Study: 27393080
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/day orally) with EE/DRSP
Study: 23111852
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fosinopril and pravastatin
Study: 12039422
Drug: Riluzole 50mg
Normalized name: RILUZOLE 50MG TAB
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 50mg capsules orally, taken twice daily
Study: 7781667
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in 108 NIDDM patients with Lp(a) concentration < 300 mgL-1
Study: 7781667
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment in subjects with elevated Lp(a) concentrations (> 300 mgL-1)
Study: 2202462
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body irradiation followed by 12 courses of high dose cytosine arabinoside (Ara‐C)
Study: 38705
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 10 mg of metopimazine, three times D-1, for two days
Study: 38705
Drug: Identically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically administered placebo
Study: 31009289
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg tolterodine and 9 mg pilocarpine
Study: 31009289
Drug: Tolterodine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine monotherapy (2 mg twice daily)
Study: 30341276
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behaviour therapy (CBT) for anxiety disorders, 4 weekly sessions
Study: 30341276
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behaviour therapy (CBT)
Study: 27875537
Drug: L-tryptophan (0.52
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (0.52 g and 1.56 g)
Study: 27875537
Drug: L-tryptophan (1.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (1.56 g)
Study: 27875537
Drug: L-tryptophan and
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan and L-leucine
Study: 27875537
Drug: Control (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (75 g glucose and 300 mL tap water)
Study: 20369718
Drug: dichlorobis (N1‐dichloromethyl‐3,5‐dimethylpyrazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: dichlorobis (N1‐dichloromethyl‐3,5‐dimethylpyrazole, copper (II) compound